Tyrosine-mediated metabolic pathways

Tyrosine-mediated metabolic pathways encompass the series of enzymatic reactions responsible for the breakdown of the amino acid tyrosine and its conversion into essential biological molecules. The catabolic arm of this pathway primarily occurs in the liver, where tyrosine is converted into fumarate and acetoacetate for energy production (Source: StatPearls, 'Biochemistry, Tyrosine Metabolism'). Additionally, tyrosine serves as the fundamental precursor for the synthesis of catecholamine neurotransmitters, including dopamine, norepinephrine, and epinephrine, which are vital for nervous system function (Source: PubChem, 'L-Tyrosine'). It is also the structural backbone for thyroid hormones (T3 and T4) and the pigment melanin, produced in the thyroid gland and melanocytes, respectively (Source: NIH, 'Tyrosine'). Clinical significance arises from genetic deficiencies in pathway enzymes, leading to conditions like Tyrosinemia, Alkaptonuria, and Albinism (Source: NORD, 'Tyrosinemia Type 1'). Pharmacological interventions often involve the use of small molecule inhibitors to block the accumulation of toxic intermediates, such as the use of nitisinone in Tyrosinemia Type I (Source: FDA, 'Orfadin prescribing information'). Furthermore, the pathway is targeted in neurology through the administration of levodopa to bypass rate-limiting steps in dopamine synthesis for Parkinson's disease treatment (Source: Mayo Clinic, 'Levodopa').

Other names

Tyrosine metabolismTyrosine catabolic pathwayCatecholamine biosynthetic pathwayThyroid hormone synthesis pathway

Enzyme inhibition to prevent toxic metabolite accumulation; Substrate reduction therapy; Precursor supplementation to restore neurotransmitter levels.